UK Firms Face Thousands Of Variations To Update Safety Information
MHRA Explains Post-Brexit Plan To Bridge Pharmacovigilance Data Gap
Executive Summary
With still no guarantee of what kind of access the UK will have to the EU’s all-important Article 57 database after the Brexit transition period ends, drug companies will have to provide key information about their pharmacovigilance systems directly to the UK medicines regulator.